$RGBPP One critical factor in the company’s favo
Post# of 144155
![](/assets/46931549/no_avatar_available_thumb.jpg)
In addition, the company has completed pre-clinical research indicating that, by inhibiting NR2F6, cancer stem cells can be converted into normal cells, thus potentially curing the patient of cancer. Additionally, activators of NR2F6 have the potential to provide relief from autoimmune diseases such as arthritis.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)